A major multi-country study presented at ESCMID Global 2026 in Munich reveals that WHO-recommended first-line antibiotics for neonatal sepsis are effective in only approximately 25% of infections in low- and middle-income countries. The findings expose a critical gap in global infant health treatment protocols, with three-quarters of neonatal sepsis cases in these regions likely resistant to current WHO-recommended treatments. The low effectiveness rate highlights the growing impact of antimicrobial resistance in resource-limited healthcare settings, creating urgent pressure on the World Health Organization to update its treatment guidelines for one of the most vulnerable patient populations.
Ineffectiveness of WHO-Recommended Antibiotics for Neonatal Sepsis
- ▪Findings on WHO-recommended antibiotics for neonatal sepsis were presented at ESCMID Global 2026 in Munich
- ▪A major multi-country study examined the effectiveness of WHO-recommended first-line antibiotics for neonatal sepsis
- ▪WHO-recommended first-line antibiotics for neonatal sepsis are effective in approximately 25% of neonatal sepsis cases in low- and middle-income countries
Antimicrobial Resistance Impact in Low- and Middle-Income Countries
- ▪The low effectiveness of WHO-recommended antibiotics for neonatal sepsis in low- and middle-income countries highlights the growing impact of antimicrobial resistance
- ▪Antimicrobial resistance is having a growing impact in low- and middle-income countries according to findings presented at ESCMID Global 2026
Perspective of World Health Organization
- ▪The World Health Organization must balance evidence of antimicrobial resistance against healthcare infrastructure limitations in low- and middle-income countries when updating treatment guidelines
- ▪The World Health Organization's current first-line antibiotic recommendations for neonatal sepsis were designed for global application across diverse healthcare settings
Perspective of Healthcare providers in low- and middle-income countries
- ▪Healthcare providers in low- and middle-income countries often lack access to second-line or reserve antibiotics when WHO-recommended first-line treatments for neonatal sepsis fail
- ▪Clinicians treating neonatal sepsis in resource-limited settings require updated evidence-based guidelines that reflect local antimicrobial resistance patterns
Story comments
Loading comments…